Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer

  • Authors:
    • Qiuyun Li
    • Wei Wei
    • Yi Jiang
    • Huawei Yang
    • Jianlun Liu
  • View Affiliations

  • Published online on: January 27, 2015     https://doi.org/10.3892/ol.2015.2908
  • Pages: 1807-1813
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

BRCA1 is a susceptibility gene that has a genetic predisposition for breast cancer. BRCA1 gene mutation is closely associated with familial hereditary breast cancer, but the BRCA1 gene mutation is rarely found in sporadic breast cancer. According to previous studies, decreased expression of BRCA1 was detected in certain types of sporadic breast cancer. Aberrant methylation of DNA promoter CpG islands is one of the mechanisms by which tumor suppressor gene expression and function is lost. The aim of the present study was to investigate BRCA1 gene expression, methylation status and clinical significance in sporadic types of breast cancer. Quantitative polymerase chain reaction (PCR) and bisulfite sequencing PCR were respectively used to detect expression differences of BRCA1 mRNA and BRCA1 methylation in the 49 cancerous and paired non‑cancerous samples from patients with breast cancer. The associations of BRCA1 expression and methylation status with the clinicopathologic characteristics were analysed. BRCA1 mRNA expression levels in the 49 breast cancer tissues were lower than those in the paired non‑cancerous tissues. There was a significant statistical difference (P=0.001). BRCA1 mRNA expression was not associated with the main clinicopathologic characteristics. Frequency of the BRCA1 promoter methylation in the breast cancerous tissues was significantly higher than that in the non‑cancerous tissues (P=0.007); BRCA1 gene methylation status was negatively correlated with mRNA expression (P=0.029); and BRCA1 methylation exhibited no association with all clinicopathological features. DNA promoter hypermethylation may be the potential mechanism accounting for BRCA1 expression silence in part of sporadic types of breast cancer. Some patients with hypermethylated BRCA1 may display favorable clinicopathological status.
View Figures
View References

Related Articles

Journal Cover

April-2015
Volume 9 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Q, Wei W, Jiang Y, Yang H and Liu J: Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer. Oncol Lett 9: 1807-1813, 2015
APA
Li, Q., Wei, W., Jiang, Y., Yang, H., & Liu, J. (2015). Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer. Oncology Letters, 9, 1807-1813. https://doi.org/10.3892/ol.2015.2908
MLA
Li, Q., Wei, W., Jiang, Y., Yang, H., Liu, J."Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer". Oncology Letters 9.4 (2015): 1807-1813.
Chicago
Li, Q., Wei, W., Jiang, Y., Yang, H., Liu, J."Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer". Oncology Letters 9, no. 4 (2015): 1807-1813. https://doi.org/10.3892/ol.2015.2908